Sign in

    Nicholas Sherwood

    Research Analyst at Maxim Group

    Nicholas Sherwood is an Equity Research Associate at Maxim Group, specializing in biotechnology sector research. He covers specific companies such as Pavmed Inc. and participates in quarterly earnings calls to provide actionable analysis and insights for institutional investors. Beginning his career in equity research with Maxim Group, Sherwood is noted for his focused expertise in biotech equities and the development of differentiated investment theses. While detailed performance metrics and formal industry rankings are not publicly available, he is actively involved in the analyst process and holds the necessary professional credentials for research roles in the financial sector.

    Nicholas Sherwood's questions to Tenon Medical (TNON) leadership

    Nicholas Sherwood's questions to Tenon Medical (TNON) leadership • Q2 2025

    Question

    Nicholas Sherwood of Maxim Group asked about the incremental physician and hospital network gained from the SciVantage acquisition and the status of cross-selling efforts. He also questioned the reimbursement landscape for the Symmetry products and requested more details on the launch timeline for the upcoming Symmetry Plus system.

    Answer

    CEO Steven Foster explained that the acquisition provides both overlapping and incremental network access, and that cross-selling and training have already begun. He clarified that the SciVantage products utilize the same existing CPT reimbursement codes as Catamaran and are supported by their own prospective clinical data. Foster detailed that the Symmetry Plus system is slated for alpha surgeries in Q4 2025 (October timeframe), with a full commercial launch anticipated in early 2026 following a 2-3 month feedback period.

    Ask Fintool Equity Research AI

    Nicholas Sherwood's questions to Tenon Medical (TNON) leadership • Q1 2025

    Question

    Nicholas Sherwood from Maxim Group asked about the expansion of the total addressable market from the new spinal fusion indication, the physician reaction to this approval, and the effectiveness of the company's targeted physician workshop strategy.

    Answer

    CEO Steven Foster explained that the new FDA clearance to augment spinal fusions significantly increases the addressable market by targeting thousands of complex spine procedures annually. He noted that physician reaction has been positive, as it addresses a well-known challenge in sacropelvic fixation. Foster believes existing SI joint fusion codes will apply. He also confirmed that a more targeted approach to physician training, including convenient in-clinic sessions, is improving engagement and adoption.

    Ask Fintool Equity Research AI

    Nicholas Sherwood's questions to JOINT (JYNT) leadership

    Nicholas Sherwood's questions to JOINT (JYNT) leadership • Q2 2025

    Question

    Nicholas Sherwood of Maxim Group questioned the impact of recent clinic sales on back-office expenses, potential restructuring costs, long-term savings from refranchising, and the methodology for testing prices under the new dynamic revenue management system.

    Answer

    CFO Scott Bowman explained that G&A reductions will be phased in carefully to ensure a smooth transition, with long-term savings expected from payroll, insurance, and other corporate overhead. CEO Sanjiv Razdan elaborated on the dynamic pricing strategy, stating it involves smaller, more frequent, and tested price adjustments in collaboration with franchisees, moving away from the infrequent, large-scale increases of the past.

    Ask Fintool Equity Research AI

    Nicholas Sherwood's questions to Mama's Creations (MAMA) leadership

    Nicholas Sherwood's questions to Mama's Creations (MAMA) leadership • Q4 2025

    Question

    Nicholas Sherwood from Maxim Group LLC questioned the progress of the Walmart rollout regarding SKU or store expansion, the strategy behind recent decreases in trade promotion spending, and the potential impact of tariffs on sourcing for facility expansions.

    Answer

    CEO Adam Michaels reported that the Walmart rollout is proceeding well, with products becoming top sellers in their set and store count increasing, though the approach remains "slow and steady." He explained that trade promotion spending was deliberately reduced from 2.6% to 2.1% of revenue to protect margins, with plans to increase it back towards the 10% goal as gross margins strengthen. Regarding tariffs, Michaels stated there is no current primary impact as sourcing is almost entirely domestic, and the company proactively stocks key equipment parts to mitigate future risks.

    Ask Fintool Equity Research AI

    Nicholas Sherwood's questions to Mama's Creations (MAMA) leadership • Q2 2025

    Question

    Speaking for Anthony Vendetti, Nicholas Sherwood asked about the promotional strategy for the Walmart launch, the rationale for the initial 2,000 stores, and details on the Costco national buy's scope and timing.

    Answer

    CEO Adam Michaels outlined a promotional plan for Walmart that includes in-store and digital marketing, such as geotargeting and QR codes. The initial store selection was a partnership with Walmart to concentrate distribution for efficiency. He described the Costco win as a major expansion, now covering six regions with a growing number of items beyond meatballs. He noted the most significant top-line impact from the Costco national buy is expected in Q4.

    Ask Fintool Equity Research AI

    Nicholas Sherwood's questions to BARFRESH FOOD GROUP (BRFH) leadership

    Nicholas Sherwood's questions to BARFRESH FOOD GROUP (BRFH) leadership • Q4 2024

    Question

    Nicholas Sherwood inquired about the expected revenue contribution from the new Pop & Go product line, the state of customer relationships amid recent production challenges, and any customer concerns regarding potential education department budget cuts.

    Answer

    Executive Riccardo Delle Coste stated that while it is early for the Pop & Go line, positive feedback and active bids are factored into the 2025 guidance, which has potential upside. He acknowledged that production issues tested customer relationships but noted strong underlying demand, with a resolution expected by the end of Q2 2025. Regarding potential education budget cuts, Delle Coste reported no negative customer feedback and suggested some changes could even be a net positive.

    Ask Fintool Equity Research AI

    Nicholas Sherwood's questions to MILESTONE SCIENTIFIC (MLSS) leadership

    Nicholas Sherwood's questions to MILESTONE SCIENTIFIC (MLSS) leadership • Q3 2024

    Question

    Nicholas Sherwood of Maxim Group inquired about Milestone's strategy for balancing the growth of its sales pipeline with converting leads, the utilization and reorder rates for the CompuFlo system, and the key drivers behind the strong performance in International Dental sales.

    Answer

    CEO Jan Haverhals explained that the company focuses on simultaneously building the sales funnel and converting leads through a continuous process. He noted strong reordering patterns from early adopters, like Dr. Dinesman's clinic, and mentioned a new clinic immediately purchased a significant volume of consumables. Regarding international dental sales, Haverhals attributed the strong quarter to resolving previous logistics issues and underlying business growth, stating the goal is to surpass the previous year's Q4 sales.

    Ask Fintool Equity Research AI

    Nicholas Sherwood's questions to HELIUS MEDICAL TECHNOLOGIES (HSDT) leadership

    Nicholas Sherwood's questions to HELIUS MEDICAL TECHNOLOGIES (HSDT) leadership • Q1 2024

    Question

    Nicholas Sherwood from Maxim Group inquired about the operational timeline for the Lovell Government Services agreement, the current demand for PoNS therapy training among new physical therapists, and the company's strategy for ensuring adequate geographic coverage of trained therapists in the U.S. pending CMS reimbursement approval.

    Answer

    Executive Dane Andreeff, with a clarification from executive Jeff Mathiesen, explained that Helius expects to begin receiving prescriptions through the Lovell agreement around early June 2024, following necessary training. Andreeff noted that demand for physical therapist training has been 'steady and upwards' in both the U.S. and Canada, driven by commercial payer interest and existing patient inquiries. He added that upon securing CMS reimbursement, Helius plans to partner with regional physical therapy chains to rapidly expand its U.S. network.

    Ask Fintool Equity Research AI